IVVD — Invivyd, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1832038 ·
Last close
$0.78
Market Cap
$230.80M
52W High
$1.80
52W Low
$0.73
ADV30
5,905,816
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 13,744,000 | 12,712,000 | -43,136,000 | -41,400,000 | 241,742,000 | 184,153,000 | 38,692,000 |
| Dec 2025 | 17,207,000 | 16,067,000 | -12,555,000 | -11,070,000 | 276,883,000 | 226,689,000 | 35,343,000 |
| Sep 2025 | 13,129,000 | 12,041,000 | -11,023,000 | -10,470,000 | 139,158,000 | 84,967,000 | 46,090,000 |
| Jun 2025 | 11,786,000 | 11,101,000 | -15,060,000 | -14,660,000 | 89,138,000 | 34,905,000 | 46,349,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-78,718,000
Investing CF
$-737,000
Financing CF
$215,522,000
CapEx
$-886,000
Dividends Paid
—
Buybacks
$-231,000
EPS Diluted TTM
$-0.45
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-995,883,000
Inventory
$262,000
Receivables
$12,209,000
ST Investments
—
EBIT TTM
$-81,774,000
Pretax Income TTM
$-77,600,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$55,866,000
EBITDA
$-81,157,000
Free Cash Flow
$-50,099,752
Enterprise Value
$61,249,008
Total Cash
$184,152,992
Total Debt
$8,626,000
Shares Out
294,607,452
Trailing EPS
$-0.29
Book Value
$0.72
ROE
-60.3%
ROA
-29.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 53,426,000 | -55,560,000 | -52,489,000 | 276,883,000 | 35,343,000 | — | -58,135,000 |
| Dec 2024 | 25,384,000 | -176,876,000 | -169,925,000 | 129,515,000 | 61,976,000 | — | -170,491,000 |
| Dec 2023 | 0 | -207,783,000 | -198,643,000 | 229,181,000 | 51,713,000 | — | -173,164,000 |
| Dec 2022 | 0 | -226,258,000 | -241,317,000 | 383,167,000 | 27,197,000 | — | -219,987,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVXL | ANAVEX LIFE SCIENCES CORP. | $231.68M | $2.50 | — |
| CGEN | COMPUGEN LTD | $226.06M | $2.39 | — |
| DTIL | PRECISION BIOSCIENCES INC | $226.03M | $8.76 | — |
| CHRS | Coherus Oncology, Inc. | $237.54M | $1.54 | — |
| TARA | Protara Therapeutics, Inc. | $242.80M | $4.32 | — |
News headlines (Yahoo Finance, 1h cache)
IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval
2026-07-06 17:39 · Yahoo
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
2026-07-06 11:01 · Yahoo
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 11:01 · Yahoo
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
2026-06-29 11:00 · Yahoo
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311
2026-06-19 07:00 · Yahoo
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
2026-06-16 11:01 · Yahoo
Invivyd doses first participants in Phase 3 COVID-19 trial
2026-06-09 16:22 · Yahoo
Invivyd Doses First Participants in Phase 3 Trial of COVID-19 Antibody VYD2311
2026-06-09 12:15 · Yahoo
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and
2026-06-09 11:01 · Yahoo
This Invivyd Insider Increased Their Holding In The Last Year
2026-06-06 13:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.